JNJ Johnson & Johnson
Company Analysis
Latest News
Johnson & Johnson's Tecvayli Gains Expanded EU Approval as Monotherapy for Multiple Myeloma
The European Commission approved an expanded indication for Johnson & Johnson's Tecvayli (teclistamab). Tecvayli is approved as a monotherapy for adults with...
Johnson & Johnson's Oral Psoriasis Pill Icotyde Gains UK Approval
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Johnson & Johnson's daily oral pill, Icotyde (icotrokinra). The drug treats...
Smith & Nephew Merger Talks With J&J Collapse Over Leadership
Advanced merger talks between Smith & Nephew and Johnson & Johnson’s orthopaedics unit, DePuy Synthes, have collapsed. The reported sticking point was a...
🟢 Johnson & Johnson is trading 3.13% up today after favorable atrial-fibrillation treatment data
Johnson & Johnson is trading at $265.84, up +3.13%, with favorable atrial-fibrillation data cited as a positive contributor to shares’ sentiment. - In its...
Johnson & Johnson Says Tremfya Sustained Fistula Remission Through 48 Weeks
Johnson & Johnson reported positive 48-week results from the Phase 3 FUZION study of Tremfya (guselkumab) in adults with fistulizing Crohn’s disease, a severe...
Johnson & Johnson's Talvey Receives Positive EU Recommendation for Expanded Myeloma Use
The European Medicines Agency's CHMP positively recommended expanding the use of Johnson & Johnson's cancer drug, Talvey (talquetamab). The CHMP endorsed...
Johnson & Johnson Targets $100B Revenue, Fueled by Oncology Drug Growth
Johnson & Johnson raised its 2026 sales and earnings guidance after exceeding third-quarter analyst expectations. The company now projects operational sales...
J&J Beats Estimates But Shares Sink 4.3%: Can a Slimmer Company Outrun Geopolitical Drag and Earnings-Quality Questions?
Shares dropped sharply as Johnson & Johnson's Q3 report delivered a paradox: headline numbers that technically cleared the bar, but underlying details that...
🔴 Johnson & Johnson is trading 4.3% down today as Middle East conflict weighed on device sales
Johnson & Johnson is trading 4.3% down at $252.52 after its October 13 third-quarter report disappointed investors, with Middle East conflict weighing on...
Johnson & Johnson’s third quarter 2026 sales matched estimates at $25.4B while Innovative Medicine outperformed
Johnson & Johnson reported third quarter 2026 results featuring solid operational sales growth of 6.0%, driven by outperformance in its Innovative Medicine...
🔴 Johnson & Johnson is trading 3.13% down in pre-market following Q3 results
Johnson & Johnson is trading at $255.48, down 3.13% in pre-market following its Q3 earnings announcement. - Before the October 13 open, adjusted EPS was...
Johnson & Johnson Q3 2026 Earnings Preview: What Analysts Expect on October 13, 2026
Consensus estimates for Johnson & Johnson's third quarter of 2026 call for revenue of $25.40 billion and adjusted EPS of $2.66, as the stock trades near...
J&J Wins Injunction Blocking U.S. Simponi Biosimilar Launch
Johnson & Johnson’s Janssen unit secured a preliminary injunction blocking the U.S. launch of the first biosimilars for its immunology drugs Simponi and...
J&J Reports 50% Five-Year Treatment-Free Remission With CARVYKTI
Johnson & Johnson reported long-term results for CARVYKTI® (ciltacabtagene autoleucel) from the Phase 2 CARTITUDE-2 study. The findings showed that a single...
Johnson & Johnson Analysis Suggests Myeloma Combo May Normalize Mortality Risk
Johnson & Johnson released a new model-based analysis of its Phase 3 MajesTEC-3 study. The analysis suggests its combination therapy for multiple myeloma could...
J&J Hits Bipolar Goal with CAPLYTA, Reducing Symptoms Within Three Days
Johnson & Johnson reported positive topline results from a pivotal Phase 3 study of CAPLYTA (lumateperone). The trial evaluated the drug for treating manic...
🟢 Johnson & Johnson is trading 3.02% up in after-hours trading after CHMP recommended TECVAYLI expansion
Johnson & Johnson is trading 3.02% up at $278.15 in after-hours trading after the European Medicines Agency’s CHMP recommended expanding TECVAYLI approval for...
J&J's TECVAYLI Gets EU Panel Backing for Expanded Myeloma Use
Johnson & Johnson announced the CHMP recommended expanding approval for its cancer drug, TECVAYLI (teclistamab). The recommendation targets adult patients with...
Johnson & Johnson Rybrevant sets survival record for rare lung cancer
Johnson & Johnson announced final Phase 3 PAPILLON study data for its drug RYBREVANT (amivantamab-vmjw). The trial evaluated RYBREVANT combined with...
J&J Nears $20 Billion Orthopedics Sale to Apollo, Streamlining Operations
Johnson & Johnson is in advanced talks to sell its DePuy Synthes orthopedics unit to Apollo Global Management. The transaction is valued at nearly $20 billion....